In the latest trading session, 1.14 million Bionano Genomics Inc (NASDAQ:BNGO) shares changed hands as the company’s beta touched 2.30. With the company’s most recent per share price at $0.20 changing hands around $0.01 or 3.21% at last look, the market valuation stands at $19.96M. BNGO’s current price is a discount, trading about -1035.0% off its 52-week high of $2.27. The share price had its 52-week low at $0.19, which suggests the last value was 5.0% up since then. When we look at Bionano Genomics Inc’s average trading volume, we note the 10-day average is 3.21 million shares, with the 3-month average coming to 2.87 million.

Analysts gave the Bionano Genomics Inc (BNGO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 3.00. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended BNGO as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Bionano Genomics Inc’s EPS for the current quarter is expected to be -0.14.

Bionano Genomics Inc (NASDAQ:BNGO) trade information

Instantly BNGO is in green as seen in intraday trades today. With action -10.36%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -89.35%, with the 5-day performance at -10.36% in the red. However, in the 30-day time frame, Bionano Genomics Inc (NASDAQ:BNGO) is -8.15% down. Looking at the short shares, we see there were 9.83 million shares sold at short interest cover period of 3.81 days.

The consensus price target for the stock as assigned by Wall Street analysts is 1, meaning bulls need an upside of 80.0% from its recent market value. According to analyst projections, BNGO’s forecast low is 1 with 1 as the target high. To hit the forecast high, the stock’s price needs a -400.0% plunge from its current level, while the stock would need to soar -400.0% for it to hit the projected low.

Bionano Genomics Inc (BNGO) estimates and forecasts

Data shows that the Bionano Genomics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -68.55% over the past 6 months, a 60.75% in annual growth rate that is considerably higher than the industry average of 17.20%. Year-over-year growth is forecast to reach -19.97% down from the last financial year.

Consensus estimates given by 3 financial analysts project the company’s revenue in the current quarter to hit an average of 6.3M. 4 analysts are of the opinion that Bionano Genomics Inc’s revenue for the current quarter will be 8.15M. The company’s revenue for the corresponding quarters a year ago was 10.72M and 8.77M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -41.24%. The estimates for the next quarter sales put growth at -7.05%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 23.59%. The 2024 estimates are for Bionano Genomics Inc earnings to increase by 77.19%.

BNGO Dividends

Bionano Genomics Inc is expected to release its next quarterly earnings report in January.

Bionano Genomics Inc (NASDAQ:BNGO)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 0.15% of Bionano Genomics Inc shares while 12.81% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 12.83%.

Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 1.36 shares estimated at $0.27 million under it, the former controlled 1.34% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.50% of the shares, roughly 505.29 shares worth around $0.1 million.